Beechwood Family Practice
Annagh Business Centre
Portadown
Craigavon BT62 3BE

+44 24 9496 6878

Search

The FDA has given fast track status to Pyxis’ drug candidate, PYX-201. This means that the review and approval process for this drug will be accelerated because it shows promise in treating a serious condition. This kind of designation is often granted to drugs that could potentially fulfill an unmet medical need. While the specific condition PYX-201 aims to treat wasn’t mentioned, similar fast-tracked drugs in the past have included names like Keytruda for cancer and Trikafta for cystic fibrosis.
Regeneron is trying for a second time to get approval for its blood cancer treatment. If possible, could you include the names of some related medications in your explanation?
Astellas, a pharmaceutical company, disagrees with European authorities about their drug Izervay, which is meant to treat geographic atrophy, a type of eye disease.
After an earlier unsuccessful trial, EyePoint’s drug Duravyu shows promising results in treating diabetic macular edema (DME).
How Helping Patients Can Make the Switch to the New Part D in 2025 Easier